These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2128982)

  • 41. [Treatment with praziquantel of schistosomiasis carriers in an endemic area, with persistent positivity after successive administration of oxamniquine].
    de Camargo S
    Rev Inst Med Trop Sao Paulo; 1982; 24(3):180-7. PubMed ID: 6760351
    [No Abstract]   [Full Text] [Related]  

  • 42. [Drug therapy of mansoni schistosomiasis].
    Zeitune JM; Ramos SR; Sugmyama LC; Côrte AA
    Arq Gastroenterol; 1980; 17(2):88-95. PubMed ID: 7213141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating antigens for assessing cure in schistosomiasis mansoni.
    Madwar MA; Hassan MM; Strickland GT
    Trans R Soc Trop Med Hyg; 1988; 82(6):881-4. PubMed ID: 3151529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Schistosoma mansoni infection with oxamniquine in Riyadh, Saudi Arabia.
    Al-Aska AK
    Trop Med Parasitol; 1985 Dec; 36(4):213-4. PubMed ID: 3937212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic studies on praziquantel and oxamniquine in intestinal schistosomiasis.
    Massoud A; Hafez AS; Hussein MM; Abdel Karim AH; el Nahaal A
    J Egypt Soc Parasitol; 1984 Dec; 14(2):599-608. PubMed ID: 6512306
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of oxamniquine and praziquantel on intrasplenic pressure and portal vein diameter in hepatosplenic schistosomiasis.
    Massoud AM; Ghoneem M; Massoud M
    J Egypt Soc Parasitol; 1986 Dec; 16(2):427-37. PubMed ID: 3782898
    [No Abstract]   [Full Text] [Related]  

  • 47. Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.
    Fallon PG; Mubarak JS; Fookes RE; Niang M; Butterworth AE; Sturrock RF; Doenhoff MJ
    Exp Parasitol; 1997 May; 86(1):29-36. PubMed ID: 9149238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerance of Kenyan Schistosoma mansoni to oxamniquine.
    Coles GC; Mutahi WT; Kinoti GK; Bruce JI; Katz N
    Trans R Soc Trop Med Hyg; 1987; 81(5):782-5. PubMed ID: 3130689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of anti-schistosomal treatment on schistosomal-specific nephropathy.
    Sobh MA; Moustafa FE; Sally SM; Deelder AM; Ghoniem MA
    Nephrol Dial Transplant; 1988; 3(6):744-51. PubMed ID: 3147416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Schistosomiasis in a mining area: intersectoral implications.
    Polderman AM
    Trop Med Parasitol; 1986 Jun; 37(2):195-9. PubMed ID: 3092337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Susceptibility of Schistosoma mansoni prevalent in Saudi Arabia to oxamniquine in experimentally infected mice.
    Amin AM; Mikhail EG
    J Trop Med Hyg; 1988 Aug; 91(4):192-5. PubMed ID: 3136251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Schistosoma mansoni: the therapeutic efficacy of oxamniquine is enhanced by immune serum.
    Lambertucci JR; Modha J; Doenhoff M
    Trans R Soc Trop Med Hyg; 1989; 83(3):362-3. PubMed ID: 2515623
    [No Abstract]   [Full Text] [Related]  

  • 53. On the distribution and control of schistosomiasis mansoni in Maniema, Zaire.
    Polderman AM; Mpamila K; Manshande JP; Gerold JL; de Vries H; Gryseels B
    Acta Leiden; 1982; 49():17-29. PubMed ID: 7188154
    [No Abstract]   [Full Text] [Related]  

  • 54. A field evaluation of three dose levels of oxamniquine in Gezira--Sudan.
    Abdel-Rahim IM; Haridi AA; Abdel-Hameed AA
    East Afr Med J; 1988 Nov; 65(11):771-7. PubMed ID: 3150352
    [No Abstract]   [Full Text] [Related]  

  • 55. Oxamniquine treatment for schistosomal polyposis: a 1-2 year follow-up study.
    el-Masry NA; Farid Z; Bassily S; Kilpatrick ME; Watten RH; Girgis NI
    J Trop Med Hyg; 1986 Feb; 89(1):19-21. PubMed ID: 3091853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effectiveness and tolerance of praziquantel in schistosomiasis].
    Groning E; Bakathir H; Salem A; Albert L; Fernández R
    Rev Cubana Med Trop; 1985; 37(2):215-9. PubMed ID: 3938555
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of schistosomiasis mansoni].
    de Carvalho SA
    Rev Paul Med; 1982; 99(2):26-8. PubMed ID: 7156674
    [No Abstract]   [Full Text] [Related]  

  • 58. Experimental schistosomiasis mansoni: electrophoretic studies on serum proteins before and after administration of oxamniquine.
    Amin AM; Mikhail EG
    J Egypt Soc Parasitol; 1989 Dec; 19(2):447-60. PubMed ID: 2504823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of praziquantel efficiency in the treatment of schistosomiasis.
    Khalil HM; el-Hawey AM; Abdel Baki MH; el-Hadi HM; Sharara MO
    J Egypt Soc Parasitol; 1986 Dec; 16(2):403-12. PubMed ID: 3097166
    [No Abstract]   [Full Text] [Related]  

  • 60. Schistosoma mansoni: tegumental surface alterations following oxamniquine treatment of infected mice.
    Amin AM; Mikhail EG
    J Egypt Soc Parasitol; 1989 Dec; 19(2 Suppl):815-26. PubMed ID: 2507653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.